CORT Stock: Price, Earnings History and SEC Filings
Corcept Therapeutics Incorporated (CORT) last traded at $81.12, down 5.62% on the latest session and down 29.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.36 against an analyst estimate of $-0.04, a beat of 1000.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CORT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $0.36 | $-0.04 | +1000.00% |
| Mar 2026 | Apr 30, 2026 | $-0.30 | $-0.30 | +0.00% |
| Dec 2025 | Feb 24, 2026 | $0.20 | $0.27 | -25.93% |
| Sep 2025 | Nov 4, 2025 | $0.16 | $0.18 | -11.11% |
CORT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How CORT reacts to earnings
Across its last 8 earnings releases, CORT moved 7.9% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | After close | +27.29% |
| 2026-04-30 | After close | +10.53% |
| 2026-02-24 | After close | -0.71% |
| 2025-11-04 | After close | +7.81% |
| 2025-07-31 | After close | +2.72% |
| 2025-05-05 | After close | -4.33% |
| 2025-02-26 | After close | -5.55% |
| 2024-10-30 | After close | +4.44% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CORT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $761M | $100M | $142M | 13.1% | $0.82 |
| 2024 | $675M | $141M | $196M | 20.9% | $1.23 |
| 2023 | $482M | $106M | $127M | 22.0% | $0.94 |
| 2022 | $402M | $101M | $120M | 25.2% | $0.87 |
| 2021 | $366M | $113M | $167M | 30.7% | $0.89 |
| 2020 | $354M | $106M | $151M | 30.0% | $0.85 |
| 2019 | $306M | $94M | $135M | 30.7% | $0.77 |
| 2018 | $251M | $75M | $115M | 30.0% | $0.60 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CORT
- 8-K · Sep 23, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 17, 2026Other events, Financial statements and exhibits
- 8-K · Jun 3, 2026Other events
- 8-K · May 28, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 17, 2026
- 8-K · Mar 25, 2026Other events, Financial statements and exhibits
Insider filing activity
CORT insiders filed 28 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CORT news
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallOct 27, 2026 · finance.yahoo.com
- What Corcept Therapeutics Stock Positive Trial Results Mean For ShareholdersOct 26, 2026 · finance.yahoo.com
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerOct 26, 2026 · finance.yahoo.com
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsOct 23, 2026 · finance.yahoo.com
- 2 cash-producing stocks to research further and 1 we find riskyOct 22, 2026 · finance.yahoo.com
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesOct 20, 2026 · finance.yahoo.com
- Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Oct 19, 2026 · finance.yahoo.com
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.